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ABSTRACT
Upper respiratory infections are among the most common ailments in humans. Evidence for 
mechanisms suggests that specifi c probiotic bacteria could reduce the risk and symptoms of 
these infections. However, the clinical evidence of probiotics in the upper respiratory tract, 
especially when colonization and the etiological eff ects are considered, is sparse. In addition, 
the safety of probiotics requires constant assessment. Th is thesis investigated the recovery of 
probiotic Lactobacillus rhamnosus GG (L. GG) from the upper respiratory tract and its eff ects 
on pathogens in this tract. In addition, the thesis assessed the adverse events of L. GG alone 
or in combination with other probiotics (Bifi dobacterium lactis BB-12 [BB12], or Lactobacillus 
rhamnosus Lc705 [Lc705], Propionibacterium freudenreichii JS [PJS], and/or Bifi dobacterium 
breve 99 [BB99]). 
In a randomized, double-blinded, placebo-controlled study, 40 children consumed per oral 
L. GG or a placebo (1:1) prior to surgery in which their adenoids were removed and a possible 
middle ear eff usion (MEE) was collected. L. GG was recovered from both the adenoid tissue and 
MEE, but it did not aff ect the fi ndings of human rhinovirus (HRV) or enterovirus (EV) in the 
samples compared to the placebo. In addition, the analysis of the bacterial pathogens in the MEE 
showed similarities in both intervention groups. No diff erences between the groups emerged in 
respiratory or gastrointestinal (GI) symptoms prior to the surgery or in pain or bleeding aft er the 
surgery.
In another randomized, double-blinded, placebo-controlled trial, an experimental HRV 
infection model was used in 59 healthy adult volunteers to investigate the eff ects of the oral 
consumption of live, heat-inactivated L. GG on the HRV load in nasopharyngeal lavage samples. 
Th e correlation of the HRV load to the subjects’ clinical symptom scores was assessed. Th e use of 
live or inactivated L. GG did not result in statistical diff erences in the HRV load, but a tendency 
to lower loads in the L. GG groups was noted. Th e HRV load positively correlated with the total 
symptom scores on day 2 and day 5 aft er inoculation.
In the fourth study, individual participant data from six randomized placebo-controlled 
probiotic studies were analyzed for adverse events (AEs), as distributed by the Common 
Terminology Criteria of Adverse Events (CTCAE). Data on 1,909 healthy subjects, including 
children, young adults, and elderly participants, revealed no statistical diff erences in AEs between 
the groups that consumed L. GG alone, L. GG in combination, or the placebo. A detailed analysis 
of three specifi c categories (respiratory diseases, gastrointestinal diseases, and infections) did not 
yield any statistical diff erences in AEs between the probiotic and placebo groups.
Based on the results, we concluded that L. GG was able to colonize the upper respiratory 
tract, but it had no eff ects on the levels of viral or bacterial pathogens or on the frequency of 
clinical symptoms in the subjects during either the intervention or the follow-up period. Th e 
nasopharyngeal HRV load was positively correlated with the subjects’ total symptom score. Th e 
use of L. GG alone or in combination did not result in AEs in the population of healthy children, 
young adults, and elderly participants.
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INTRODUCTION
Th e interest in gut microbiota has emerged in recent decades. Gut microbiota has been associated 
with the promotion of health, the increased the risk of disease, and the maintenance of some 
diseases. Upper respiratory infections caused by viruses are among the most common health 
problems in humans (Fendrick et al. 2003). In addition to the misery of sickness, these infections 
result in a signifi cant burden on society in terms of healthcare visits, absences from work, and 
reduced school attendance. In addition, unnecessary medical costs are incurred. Th e careless use 
of antibiotics during respiratory tract infections has resulted in the constantly growing resistance 
of microbes to antibiotics (Roca et al. 2015). Th e complications of upper respiratory infections, 
such as otitis and sinusitis, also result in high expenses and expose patients to potentially harmful 
operations. If viral upper respiratory infections could be prevented and treated, these outlays 
would be minimized. 
According to a panel of international experts, “probiotics are live microorganisms that, 
when administered in adequate amounts, confer a health benefi t on the host” (WHO/FAO 2011; 
Hill et al. 2014). Th e strain should be precisely defi ned (i.e., identifi ed and characterized), the 
dose should be defi ned, the health claim should be indicated, and the safety should be assessed. 
Th e properties of probiotics vary widely according to the strain. Even the manufacturing process 
infl uences the properties of certain strains (Grześkowiak et al. 2011).
Lactobacillus rhamnosus GG (L. GG, ATCC 53103) is one of the most-oft en studied 
probiotics. Th is bacterial strain of human origin has been isolated from the human gut. Its 
benefi ts in GI disorders have been demonstrated (Vitetta et al. 2014), and similar eff ects have 
been found in upper respiratory infections (Hojsak et al. 2010a, Hojsak et al. 2010b). Although 
the colonization of the gut and the fecal recovery of specifi c probiotics, including L. GG, 
have been extensively studied, little information is available on the colonization of the upper 
respiratory epithelium where the lymphatic system is present. Even less is known about the 
eff ects of the possible colonization of the related mucosal tissues. Probiotics are widely added 
to commercial dairy products and food products, and they are increasingly consumed as 
supplements (Siró et al. 2008). Th e safety of L. GG has been monitored since 1989. A few case 
reports have describe infections caused by probiotics, such as bacteremia, endocarditis, and 
internal organ abscesses. However, the incidence of Lactobacillus bacteremia has remained stable 
although the consumption of probiotic products has increased exponentially (Salminen et al. 
2002). Infections seem to be very sparse and aff ect mostly immunocompromised or critically ill 
patients (Boyle et al. 2006). Probiotic consumption has been documented as safe in neonates and 
even in preterm infants (AlFaleh, Anabrees 2013). A report from Finland suggested that L. GG is 
safe for premature infants based on 12 years of its administration to all premature and very low 
birth weight infants born in the area around one university hospital (Luoto et al. 2010).
In the USA, probiotics are regulated by Th e Food, Drug, and Cosmetic Act (Degnan 2008). 
Th e Food and Drug Administration assigns probiotic products to one of several regulatory 
categories: food, medical food, dietary supplement, or drug or biological products, and 
the regulation of the product depends on the category. In Europe, the European Food Safety 
Authority panel on Dietetic Products, Nutrition and Allergies assesses the scientifi c evidence of 
potential probiotic health claims and the safety of novel probiotics. 
Th e safety of such products must be comprehensively studied. However, few previous studies 




2.1  Probio  cs in the respiratory tract
2.1.1 Probio  cs and their health e  ects
Probiotics should fulfi ll the following criteria: they must survive in the gastrointestinal tract and 
be able to proliferate in the gut; they should benefi t the host through growth and/or activity in 
humans; and they should be non-pathogenic and non-toxic (Wassenaar et al. 2008). Probiotic 
micro-organisms exist in multiple genus, species, and strains. Although recent evidence suggests 
that they have some common health eff ects, they have many strain-specifi c health eff ects (Hill et 
al. 2014). Th e most common probiotic organisms are bacteria from the genus Bifi dobacterium 
and the genus Lactobacilli (Guarner et al. 2012). Th e fi ndings of broad meta-analyses of strain-
specifi c probiotics support that common health benefi ts are derived from consuming an 
adequate dose of any safe strain of a species that is already known to be an eff ective probiotic. 
For example, a meta-analysis of diff erent strains and 10,351 patients found that probiotics had a 
positive eff ect on eight gastrointestinal diseases across the all studied probiotic species (Ritchie, 
Romanuk 2012). However, the results showed diff erences in effi  cacy regarding specifi c diseases 
and specifi c diff erences in strains. 
Professional medical organizations have made clinical recommendations of well-defi ned 
specifi c probiotics for specifi c clinical conditions. In particular, gastrointestinal conditions have 
shown health eff ects: probiotics are recommended in the treatment and prevention of acute 
gastroenteritis, necrotizing enterocolitis, and antibiotic-associated diarrhea (Ebner et al. 2014). 
Th ey can be supplemented with infant formula to enhance growth and improve clinical outcomes 
although evidence is still lacking (Braegger et al. 2011). Some evidence exists to support the 
use of probiotics in several conditions: constipation, irritable bowel syndrome, infl ammatory 
bowel diseases, lactose intolerance, allergies, atopic eczema, certain cancers, hepatic diseases, 
hyperlipidaemia, Helicobacter pylori infection, genitourinary tract infections, and oral health 
(Brown, Valerie 2004, Kopp-Hoolihan 2001). In 2015, the World Allergy Organization (WAO) 
convened a guideline panel to develop evidence-based recommendations for the use of probiotics 
in the prevention of allergy (Fiocchi et al., 2015). Th e European Pediatric Gastroenterology, 
Hepatology and Nutrition (ESPGHAN) association has also established recommendations for the 
use of probiotics in the prevention and treatment of acute gastroenteritis in children (Szajewska 
et al., 2014) ESPGHAN recommends the use of specifi c, well-studied probiotics to prevent and 
treat acute gastroenteritis in infants and children and to reduce the side-eff ects associated with 
antibiotics (Szajewska et al., 2014). In addition, the meta-analysis of a specifi c probiotic strain 
concluded that L. GG was eff ective in preventing antibiotic-associated diarrhea in children and 
adults who were treated with antibiotics for any reason (Szajewska and Kołodziej, 2015).
Th e heat inactivation of probiotic bacteria has some advances over live bacteria. It prolongs 
shelf life and facilitates storage and transportation. Heat-inactivated probiotics have been studied 
mainly in animals, where they have shown favorable eff ects in immune responses (Chen et al. 




2.1.2 Mechanisms of ac  on
Th e mechanisms of the action of probiotics in viral and bacterial infections are not completely 
understood. Specifi c probiotics show strain-specifi c potential for reinforcing the integrity of 
the intestinal epithelium and regulating immune components. In regulating complex immune 
responses, the gastrointestinal tract from the oral cavity to the rectum is considered the largest 
immune interface with the environment (MacDonald et al. 2011). Th e potential mechanisms 
are studied mainly in the gastrointestinal epithelium. Some postulated mechanisms of probiotic 
action in intestinal epithelial defense are presented in Figure 1.
Figure 1. Possible mechanisms by which probiotic bacteria modulate intestinal defense responses. 
Adapted from Wan et al. (2015)
It is possible that probiotic bacteria could bind to an invading virus, thus inhibiting virus 
attachment to the host-cell receptor (Salminen et al. 2010). Lactic acid bacteria may exert 
antiviral activity by the following: 1) direct interaction as an adsorptive or trapping mechanism; 
2) stimulation of the immune system by interleukin, natural killer cells, Th 1 immune response 
activity, and IgA production; 3) production of antiviral agents (e.g., hydrogen peroxide, lactic 
acid, and bacteriocins) (Al Kassaa et al. 2014).
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2.2 Acute upper respiratory infec  ons
2.2.1 Viral infec  ons
Acute viral upper respiratory infections (URI), which are also known as the common cold, are 
among the most common health problems in humans (Heikkinen, Järvinen 2003). Th e economic 
burden on society of the otherwise usually benign disease is enormous because of absences from 
work, school, and daycare, as well as the utilization of health care providers and treatments. In 
the USA, 25 million health care visits a year are made because of URI (Gonzales et al. 2001), 
and in Finland, 2.4 million visits are made annually for upper and lower respiratory infections 
(Lumio et al. 1996). On average, children 1-2 years of age experience 3-8 respiratory infections 
yearly, and children over 5 years of age experience about three respiratory infections yearly (Wald 
et al. 1991, Nokso-Koivisto et al. 2006).
More than 200 viruses are known to cause respiratory infections in humans (Eccles 
2005). Major pathogens that induce URIs are human rhinoviruses (HRVs) from the family 
Picornaviridae, genus Enterovirus (Fendrick 2003). Other common causative agents are 
respiratory syncytial virus (RSV), parainfl uenza virus, enterovirus (EV) from the family 
Picornaviridae and genus Enterovirus, coronavirus, infl uenza virus, and adenovirus (Passioti et 
al. 2014). Of these, infl uenza virus, RSV, and parainfl uenza virus are more frequent causes of 
lower than upper respiratory infections (Mäkelä et al. 1998, Heikkinen, Järvinen 2003, Nokso-
Koivisto et al. 2006). Th e symptoms of URI arise aft er an incubation period that varies depending 
on the causative agent. 
Th e symptoms of HRV infection include sore throat, sneezing, nasal obstruction and 
discharge, hoarseness, cough, malaise, myalgia, and chills. HRV can also induce acute otitis 
media (AOM) and rhinosinusitis (Jacobs et al. 2013, Nokso-Koivisto et al. 2015). EV is 
traditionally associated with severe clinical conditions, such as meningitis, encephalitis, and 
neonatal sepsis, but it is also recognized as a common causative agent in respiratory infections 
and AOM, inducing 10% of common colds in Finnish children (Ruohola et al. 2009). 
2.2.2 Experimental rhinovirus infec  on
Th e understanding of pathogenetic mechanisms in URIs is mainly derived from experimental 
HRV inoculation studies in animals and humans. An infectious dose of HRV is small. Viruses are 
mainly transmitted by small aerosol particles and direct or indirect contact with contaminated 
secretions to anterior nasal mucosa or eye and eventually to the nasal cavity through the 
ductus lacrimal. Mucociliary action in the nasal cavity transports viruses to the nasopharynx 
and adenoid tonsil. Th e viral load peaks 48 to 72 hours aft er inoculation and rapidly produces 
new variants via mutations (Cordey et al. 2010). In the adenoid epithelium, HRV binds to the 
specifi c intercellular adhesion molecule 1 (ICAM-1) to gain access to the cell and then starts to 
replicate and spread (Winther et al. 2002). Infection of the epithelial cells results in the increased 
expression of several proinfl ammatory cytokines, such as interleukins (IL-1β, IL-6, IL-8), 
tumor necrosis factor (TNF)-α, leukotrienes, histamine, and kinins; in addition, neutrophil and 
monocyte recruitment is observed (van Kempen et al. 1999, Naclerio et al. 1988, Winther 2011). 
In HRV infection, the fi rst symptoms occur 10 to 16 hours aft er HRV inoculation in the nose 
and peak aft er 2 to 3 days (Gwaltney Jr 2002). An average duration of infection is 7.5 days, but a 
quarter of infections can last as long as 3 weeks. Experimental HRV infection studies have several 
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advantages over natural observational wild type studies: the easier utilization of controlled 
clinical settings, selection of a focused population, the use of defi ned inoculum and challenge 
dose, uniform timing, and the possible identifi cation of co-infections. Th e disadvantages include 
milder infections and the possible disturbance of other virus infections. Several studies have been 
conducted using an experimental HRV model in a healthy adult population and in a population 
60 years and older with chronic pulmonary diseases (del Vecchio et al. 2015).
2.2.3 Treatment and preven  on of viral upper respiratory infec  ons
Several multidrug cocktails, herbal and natural preparations, and dietary supplements are used 
in the treatment of URI, but their clinical eff ects are minimal. Even though antibiotics do not 
infl uence viral infections, they are widely used in treatment. In the USA, 30% of patients with 
URI were prescribed antibiotics at a medical costs of $726 million (Gonzales et al. 2001). Th e 
inevitable result is the ever-increasing resistance to antibiotics, which is emerging a global 
threat (Roca et al. 2015). Generally, a symptom-relief medication is used in URI, such as topical 
anesthetics, non-steroidal anti-infl ammatory drugs (NSAIDs), antihistamines, anticholinergic 
nasal compounds, pseudoephedrine, expectorants, mucolytic cough medication, codeine, zinc, 
vitamin C, and Echinacea. However, according to a review based on seven Cochrane reviews 
(Arroll 2005), most of these are probably not effi  cacious against the common cold. 
Data from experimental HRV infection trials have contributed to the information about 
possible treatment strategies. Intranasal oxymetazoline (used as a decongestant) reduced viral 
load signifi cantly day two aft er inoculation but had no eff ect on the subjects’ symptoms (Winther 
et al. 2010). In another experimental study, a recombinant soluble ICAM-1 (tremacamra) 
signifi cantly reduced total symptom scores and the proportion of subjects with clinical colds 
(Turner et al. 1999). However, the treatment has not been standardized. Th e neuraminidase 
inhibitors oseltamivir and zanamivir are recommended for preventing and treating seasonal and 
pandemic infl uenza. According to a recent Cochrane review, these drugs reduced the time to 
the fi rst alleviation of symptoms by approximately half a day in adults, and they reduced the risk 
of symptomatic infl uenza when used as a prophylactic drug (number needed to treat to benefi t 
[NNTB] = 33 for oseltamivir and NNTB = 51 for zanamivir) (Jeff erson et al. 2014).
No medical treatment is available for preventing URIs, which can be avoided by interrupting 
viral transmission by practicing good hand hygiene, cleaning surfaces, and avoiding touching the 
eyes or nose (Savolainen-Kopra et al. 2012, Uhari, Möttönen 1999). Eff orts to develop a fl u vaccine 
have not been successful. Indeed, the fact that HRV presents with over 150 serotypes hinders the 
development of a vaccine (Glanville, Johnston 2015). At present, only the commercially available 
vaccines against viral URI are administered against infl uenza. 
2.2.4 Acute o   s media
Acute otitis media (AOM) is defi ned as an acute, short-term, clinically verifi ed infection of the 
middle ear, where the tympanic membrane appears infected and middle ear eff usion exists. At 
least one general or topical infection-related symptom or fi nding also needs to exist. AOM is the 
most common complication of URI, the leading cause of the visits of sick children to the doctor, 
and the main reason that antibiotics are prescribed for children (Klein 2000). In Finnish children, 
63% of AOM cases occurred during the fi rst week of URI (Koivunen et al. 1999). Approximately 
80% of children experience at least one episode of AOM before the age of three, which peaks 
in children aged 6 to 15 months (Harmes et al. 2013). Viral URI increases the risk of AOM by 
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promoting the replication of bacteria, and the infl ammation of the nasopharynx and eustachian 
tube facilitates bacterial entry into the middle ear (Uhari et al. 2000). However, in addition to 
bacteria, respiratory viruses can act as a causative agent in AOM, and coinfections are common 
(Pettigrew et al. 2011, Nokso-Koivisto et al. 2015). In particular, HRV, EV, and RSV have been 
found to be present in the nasopharynx and/or middle ear eff usion (MEE) in two-thirds of 
children with AOM (Nokso-Koivisto et al. 2004). Th e bacteria most-oft en implicated with AOM 
are Streptococcus pneumoniae (S. pneumoniae), Haemophilus infl uenzae (H. infl uenzae), and 
Moraxella catarrhalis (M. catarrhalis). Aft er the introduction of the pneumococcal vaccine, H. 
infl uenzae became the most prevalent pathogen in severe and recurrent AOM (Coker et al. 2010, 
Harmes et al. 2013). 
Several guidelines exist to aid clinicians in the challenging diagnosis of AOM. Myringotomy 
is considered the gold standard for diagnosing middle ear fl uid. However, the procedure is not 
practical in daily clinical practice. Th erefore, three criteria are used in diagnosing an AOM: 
1) evidence of middle ear infl ammation; 2) presence of MEE; 3) acute symptoms of infection 
(Coker et al. 2010). Th e symptoms of AOM include fever, otalgia, irritability, otorrhea, lethargy, 
anorexia, and vomiting. However, the diagnosis cannot be based on symptoms only (Qureishi 
et al. 2014). Furthermore, indicating MEE is challenging; simple otoscopy is 60 to 70% accurate 
in diagnosing MEE. In AOM, bulging of the tympanic membrane or new onset otorrhea, not 
secondary to otitis externa, should be present for the diagnosis. Th e use of pneumatic otoscopy 
elevates the sensitivity and specifi city for diagnosing MEE by skilled hands up to 70 to 90%. 
Tympanometry or acoustic refl ectometry may be valuable adjuncts in predicting the presence or 
absence of MEE with sensitivity and specifi city of 40 to 90% (Rogers et al. 2010, Muderris et al. 
2013). Tympanometry has also been successfully used in monitoring the disappearance of the 
eff usion (Renko et al. 2006).
2.2.5 Treatment and preven  on of acute o   s media
Because the origin of AOM may be viral, bacterial, or a combination thereof, not all patients 
benefi t from antibiotic therapy. A meta-analysis demonstrated that 80% of AOM resolved 
spontaneously in 2 to 7 days and 15 children needed to be treated with antibiotics to prevent one 
child from having some pain aft er two days (Glasziou et al. 2011). Prompt analgesic medication 
should be used because antibiotic therapy does not provide symptomatic relief in the fi rst 24 
hours. Th e clinical practice guidelines of the American Academy of Family Physicians and 
Pediatrics suggest antibiotic therapy for AOM in children 6 months or older with severe signs 
and symptoms. Antibiotic therapy is also recommended for children younger than 24 months 
with bilateral AOM and non-severe signs and symptoms. Clinicians should prescribe antibiotic 
therapy or off er observation with close follow-up in non-severe unilateral AOM in young 
children and non-severe AOM in older children (Lieberthal et al. 2013). However, the increasing 
prevalence of antibiotic-resistant bacteria makes antibiotic management diffi  cult. Guidelines 
recommend amoxicillin or penicillin as the fi rst-line treatment (Acute otitis media: Current 
Care Guidelines Abstract, 2010) (Lieberthal et al. 2013). According to the Finnish Study Group 
of Antimicrobial Resistance (FiRe), the resistance of H. Infl uenzae to amoxicillin and sulfa-
trimethoprim is around 25%. Th e resistance of S. pneumoniae to penicillin is around 15%, to 
erythromycin around 20%, to clindamycin around 11%, and to sulfa-trimethoprim around 14%. 
M. catarrhalis is resistant to amoxicillin (FiRe, National Institute for Health and Welfare 2014).
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Ventilation tubes are commonly used in recurrent AOM (rAOM = over three episodes in 
six months or over four episodes in 12 months) although literature on surgery in rAOM is scant. 
A Cochrane review of two studies concluded that ventilation tubes reduced AOM episodes in 
the fi rst 6 months, but further research is warranted (McDonald et al. 2008). A Finnish study 
group found tympanostomy tubes with or without adenoidectomy to be eff ective in preventing 
rAOM episodes in children younger than 2 years (Kujala et al. 2012). However, surgery did not 
provide any additional benefi t in the quality of life of children with rAOM (Kujala et al. 2014). 
In contrast, adenoidectomy is not recommended as the fi rst-line surgery for rAOM (Koivunen 
et al. 2004). 
Th e best way to prevent AOM is to prevent URI. A recent Cochrane review of infl uenza 
vaccines found a modest decrease of AOM in infants and children (Norhayati et al. 2015). 
Pneumococcal conjugate vaccines have reduced AOM caused by pneumococcal serotypes 
contained in the vaccine (Pelton et al. 2013). In addition, in a meta-analysis of fi ve studies on the 
outcome of AOM, pneumococcal vaccine resulted in a reduction by 29% in all S. pneumoniae 
serotypes among children who received the heptavalent pneumococcal conjugate vaccine 
(PCV7) before 2 years of age (Pavia et al. 2009). In Finland, a ten-valent pneumococcal conjugate 
vaccine (PCV10) has been implemented in the national vaccination program since 2010, and 
an infl uenza vaccine has been implemented since 2007. In addition, xylitol has potential for the 
prevention of AOM, but not when only used in acute URI (Tapiainen et al. 2002, Uhari et al. 
2000).
2.2.6 O   s media with e  usion
Otitis media with eff usion (OME) is defi ned as a collection of fl uid in the middle ear without 
the signs or symptoms of an acute ear infection. OME is the most common disease of the ear in 
childhood; approximately 90% of children present with OME before school age (Minovi, Dazert 
2014, Rosenfeld et al. 2004). It is also the main reason for impaired hearing in children; the 
majority of children show a conductive hearing loss of 25 dB, and approximately 20% exceed a 
hearing level of 35 dB (Rosenfeld et al. 2004). Th e eff ects of hearing loss on children´s receptive 
and expressive language remain unclear (Lang-Roth 2014). Other possible symptoms of OME 
are otorrhea, tinnitus, otalgia, and pressure sensation. Th e pathogenesis of OME consists of 
the spontaneously impaired function of the Eustachian tube or an infl ammatory response aft er 
AOM. Th e majority of the episodes resolve spontaneously within three months, but 30 to 40% of 
children suff er from recurrent OME, and 5 to 10% might persist for a year (Tos 1984, American 
Academy of Family Physicians et al. 2004). Adults have a considerably lower prevalence of OME, 
but underlying diseases oft en emerge: paranasal sinus disease, smoking-induced nasopharyngeal 
lymphoid hyperplasia, adenoid hypertrophy, and head and neck tumors are identifi ed as inducing 
factors (Qureishi et al. 2014). 
Th e occurrence of H. infl uenzae and HRV in MEE in OME is common (70% and 44%, 
cultivated and analyzed by PCR, respectively) (Stol et al. 2013). Th e nasopharyngeal carriage of 
two or three bacterial pathogens was found to be associated with the bacterial fi ndings in MEE. 
In another study, HRV and EV were found from 32% of MEE samples from children with OME 
(Rezes et al. 2009). Bacterial biofi lms have also been recognized as important in the etiology of 
OME (Hall-Stoodley et al. 2006). 
Th e guidelines advise clinicians to use pneumatic otoscopy as the primary diagnostic 
method for OME, and OME should be distinguished from AOM. Tympanometry is an optional 
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method for confi rming the diagnosis (American Academy of Family Physicians et al. 2004, 
Rosenfeld et al. 2004). 
2.2.7 Treatment and preven  on of o   s media with e  usion
Children who are not at risk for speech, language, learning delay, or diffi  culties should be 
managed by watchful waiting for three months. Th e risks include permanent hearing loss 
independent of OME, speech delay, autism-spectrum disorders, syndromes, craniofacial 
disorders, visual impairment, or developmental delay. Th ese children should be distinguished 
and evaluated promptly (Rosenfeld et al. 2004). 
A Cochrane systematic review of a database concluded that routine antibiotic therapy is 
not supported in the treatment of OME (van Zon et al. 2012). A surgical intervention should 
be considered if bilateral OME persists over three months and hearing level is 25 to 30 dB at 
0.5 to 4 kHz or less and if the child is at risk for speech, language, or learning. Tympanostomy 
(ventilation tube insertion) is the preferred initial procedure, and adenoidectomy should not be 
performed unless a distinct indication (nasal obstruction, chronic adenitis) exists (Khanna et 
al. 2008). Adenoidectomy with myringotomy with or without tubes is recommended for repeat 
surgery in children older than 2 years (Rosenfeld et al. 2004). 
Vaccines preventing AOM could be considered to prevent OME because the condition 
commonly persists aft er AOM. Epidemiological evidence exists that the risk of OME is increased 
by passive smoking, bottle feeding, low socioeconomic group, and exposure to a large number 
of other children (Williamson 2011). However, there is no evidence to show whether modifying 
these risk factors would prevent OME.
2.3 Coloniza  on of upper respiratory tract with probio  cs
Colonization of the gut epithelium by probiotics has been extensively studied (Alander et al. 1999, 
Ramakrishna 2009, Bermudez-Brito 2012). Mucosal adhesion is incorrectly taught as essential 
for both non-immune and mucosal immune defense mechanisms. For example, noncolonizing 
probiotics, such as Lactobacillus casei, may exert their functions in a transient manner or by 
infl uencing the existing microbial community (Ohland, MacNaughton 2010). Th us far, few 
trials have investigated the colonization of upper respiratory tract with probiotics. In a pilot 
study, probiotic Lactobacillus plantarum DSM9843 was cultured from the tonsillar surfaces of 6 
subjects up to eight hours aft er the per oral consumption of fermented oatmeal gruel enriched 
with this probiotic (Stjernquist-Desatnik et al. 2000). Another small population trial investigated 
the recovery of Streptococcus salivarius K12 in the nasopharynx and oral cavity aft er oral intake 
(Power et al. 2008). In this study, one of 19 nasopharyngeal cultures was reported positive for the 
probiotic, and it was recovered from three adenoids of the seven examined. Tonsillar recovery 
of L. GG aft er per oral consumption was studied in 57 young adults in a placebo-controlled 
and randomized trial (Kumpu et al. 2013a). L. GG was recovered in 40% of the L. GG groups’ 
tonsillar samples and in 30% of the placebo groups’ samples. In a recent trial, 20 adults were 
treated with intranasal Streptococcus salivarius 24SMBc for three days (Santagati et al. 2015). Th e 
results showed that 95% of the subjects were colonized in the nasopharynx with the probiotic at 
least four hours aft er spray administration; colonization persisted for at least six days in in 55% 




Table 1. Characteristics of the previous studies investigating the colonization of upper respiratory 
tract with probiotics.
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2.4 Clinical e  ects of probio  cs in the upper respiratory tract
Th e prevention of upper respiratory infections by the use of probiotics has been studied in several 
trials. For instance, L. GG alone or in combination with other probiotics was shown to reduce 
the incidence or risk of URI in children (Hatakka et al. 2001, Rautava et al. 2008, Kumpu et al. 
2012). A recent systematic review found a favorable outcome of the use of probiotics in reducing 
the episodes of new respiratory infection in children (de Araujo et al. 2015). However, further 
studies are required to confi rm these results. A recent Cochrane database review of the use of 
probiotics in URI found 13 randomized controlled trials with participants in several age groups 
(see Table 2). (Hao et al. 2015). Probiotics were found to be better than the placebo in reducing 
the number of subjects who experienced acute URI, the mean duration of acute URI, the number 
of antibiotic prescriptions, and cold-related school absences. However, the quality of evidence 
was considered low or very low.
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Table 2. Characteristics of the included randomized controlled studies in Hao et al. 2015








aged 18-65 (n = 
318)
RDBPC, 3 mo L. plantarum and 
L. paracasei (1x109 
cfu)
Incidence of common 
cold episodes 




aged 1-5 (n = 398)
RDBC, 3 mo L. rhamnosus 
HN001 (1010 cfu)
Number and duration 
of URI 




facilities (n = 154)
RDBPC, 5 mo L. casei strain 
Shirota (4x1010 
cfu)
Number of acute URI 
and symptom score 
Fujita 2013
Day-care children  
aged 13-86 mo (n 
= 281)
RDBPC, 3 mo L. rhamnosus GG 
(109 cfu)
Risk of URI 











L. rhamnosus GG 
(109 cfu)
Risk of URI 





69-80 (n = 60)
RPC, 2 or 3 mo L. bulgaricus (1.8-
3.2x1010 cfu) and 
S. thermophilus 
(5.7-7.9x1010 cfu)
Risk of URI 




or school children 
aged 3-6 (n = 638)
RDBPC, 3 mo L. casei 
(2x1010 cfu), S. 
thermophiles and 
L. bulgaricus (109 
cfu)





formula aged 0-2 
mo (n = 81)
RDBPC, 12 mo L. rhamnosus and 
B. lactis BB-12 
(1x1010 cfu)
Risk of URI 




aged 8-13 (n = 80)
RDBPC, 3 mo L. acidophilus and 
B. bifi dum (1x109 
cfu)
Symptoms of URI 
Absences from school 




6-25 mo (n = 100)
RPC, 3 mo L. acidophilus and 
L. casei (109 -1010 
cfu)




aged 3-12 years (n 
= 251)




aged 18-24 (n = 
198)
RDBPC, 3 mo L. rhamnosus GG 
and B. animalis 
ssp. lactis BB-12
Duration or URI 
Median severity score 
Missed school days 
Smith 2013
Healthy adults, 




L. gasseri, B. 
longum, and B. 
bifi dum (5x107 cfu)
Duration of URI 
Total symptom score 
Days with fever during 
URI 
de Vrese 2005
RD = randomized, B = placebo-controlled, P = prospective, C = clinical trial
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A meta-analysis of randomized, placebo-controlled trials indicates that L. GG is able to reduce the 
incidence of AOM and antibiotic prescriptions and decrease the risk of URI in children (Liu et al. 
2013). However, in otitis-prone children with nasopharyngeal pathogen colonization, L. GG did 
not reduce the occurrence of AOM (Hatakka et al. 2007a). A novel treatment model of intranasal 
spray bacteriotherapy with Streptococcus sanguinis was found to be eff ective in decreasing MEE 
in children with prolonged OME (Skovbjerg et al. 2009). Statistically signifi cant recovery was 
achieved with Streptococcus sanguinis, and a more modest, yet positive eff ect was achieved with 
L. GG. In otitis-prone children, the consumption of L. GG, Lc705, BB99, and PJS signifi cantly 
reduced the number of positive human bocavirus nasopharyngeal samples (Lehtoranta et al. 
2012). Th e colonization of the epithelium of the upper respiratory system with specifi c probiotics 
or lactic acid bacteria is not well known. Lactobacillus plantarum DSM 9843 was recovered from 
the tonsillar surface aft er oral administration, suggesting that the strain may possess the capacity 
to adhere to tonsillar cells (Stjernquist-Desatnik et al. 2000). Streptococcus salivarius K12 was 
cultured from the nasopharynx of infants aft er the consumption of an oral powder prepared with 
this probiotic bacterium (Power et al. 2008). Recently, L. GG was recovered from tonsil tissue 
aft er oral consumption, and prolonged adhesion (over 4 weeks) was suspected (Kumpu et al. 
2013a). Th e consequences of colonization are unknown. An in vitro experiment indicates that 
L. GG is able to inhibit the adherence of S. pneumoniae to human epithelial cells (Wong et al. 
2013). Two review studies suggested that specifi c probiotics interact with pathogens and have the 
potential to reduce pathogen colonization in the nasopharynx, thus potentially reducing AOM 
and URI (Salminen et al. 2010, John et al. 2013).
2.5 Safety of probio  cs
2.5.1 Infec  ons caused by probio  cs
Because probiotics are live bacteria, and any live bacterium can potentially cause an infection, 
concerns about their safety have been discussed. Although the use of probiotics is generally 
recognized as safe, there are some case reports of infections caused by probiotics. In a four-
year study in southern Finland, only eight Lactobacillus bacteremia were found, none of which 
was identifi ed as L. GG (Saxelin et al. 1996). However, a rapid increase in L. GG consumption 
occurred in Finland in the 1990s. Nonetheless, increases in Lactobacillus-associated bacteremia 
were not implicated, and the incidence remained stable at 0.3/100,000 inhabitants/year (Salminen 
et al. 2002). In a cohort of 89 cases of Lactobacillus bacteremia, the majority of patients suff ered 
from serious underlying conditions, such as malignancies or severe gastrointestinal diseases, 
and the majority had undergone at least one surgical intervention and several courses of 
antibiotics (Salminen et al. 2004). In this study, among 48 Lactobacillus isolates, 11 could not be 
diff erentiated from L GG. Furthermore, Lactobacillus bacteremia was found to be present with 
high mortality (26% in one month, 48% in one year). 
Lactobacillus has also been implicated as an agent associated with human endocarditis in 
a few case reports (Husni et al. 1997, Mackay et al. 1999). A diseased heart valve was identifi ed 
as a predisposing factor. In extremely rare cases, Lactobacillus can cause a liver abscess. In seven 
described cases, six had a predisposing factor; diabetes mellitus, immunosuppression, or a history 
of malignancy (Chan et al. 2010). However, the overall mortality of subjects with liver abscess 
was low. Case reports on Lactobacillus splenic abscess (Doi et al. 2011) and lung abscess (Shoji 
et al. 2010) have been sporadic. Overall, underlying conditions, such as immunosuppression, 
Literature Review
20
major gastrointestinal diseases, other severe illnesses, central venous catheters, or other surgical 
interventions, seem to be risk factors for infections caused by Lactobacillus. However, probiotics 
are used safely by pregnant women (Elias et al. 2011), immunocompromised patients (van den 
Nieuwboer et al. 2015a), and cancer patients (Redman et al. 2014). However, a systematic review 
of people with cancer identifi ed fi ve case reports of probiotic-related bacteremia or fungemia 
(Redman et al. 2014).
2.5.2 Other adverse events
Numerous studies have investigated the effi  cacy of probiotics in diff erent illnesses or conditions. 
However, studies focusing on the possible adverse events (AE) are scarce. In most effi  cacy studies, 
AEs are not mentioned or they are acknowledged in a sentence or two. Th e most commonly 
reported AEs in the consumption of probiotics are of gastrointestinal origin, such as bloating, 
constipation, diarrhea, or stomachache. A study group reported probiotic and prebiotic safety 
in infants under 2 years (van den Nieuwboer et al. 2014) and children under 18 years (van den 
Nieuwboer et al. 2015b). In the infant study, 65 trials or follow-up studies were evaluated, and the 
results indicated the safe use of probiotics regarding the evaluated strains. Major safety concerns 
were not encountered and, in general, AEs were not considered related to the study product, 
which generally was well tolerated. However, the reporting of AEs was found to be imprecise, 
inconsistent, and incomplete, thus limiting the generalization of the results. Th e other study 
evaluated 74 clinical trials, showing similar results in terms of safety and the poor reporting of 
AEs. Overall, AEs were encountered more frequently in the placebo group than in the group that 
received probiotics or prebiotics. 
Th e study also reported the safety of probiotics and prebiotics in immunocompromised 
adults (van den Nieuwboer et al. 2015a). Th ey concluded that AEs occurred more frequently in 
the placebo group than in the probiotic/prebiotic group, and no serious AEs were related to the 
products consumed. Inadequate reporting of AEs was indicated, and future studies were strongly 
recommended to assess a structured method, such as the Common Terminology of Adverse 
Events (CTCAE), for reporting AEs. 
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3 AIMS OF THE STUDY
Th e aims of this thesis were to study the colonization of probiotic Lactobacillus rhamnosus GG 
in the upper respiratory tract, its eff ects on viral and bacterial pathogens in the upper respiratory 
tract, and the possible adverse events related to LGG use alone or in combination with other 
probiotics.
Th e specifi c aims are as follows:
1. Characterize how a three-week oral consumption of live L. rhamnosus GG infl uences the 
colonization of L. GG in the nasopharynx and middle ear of young children (I, II).
2. Determine whether the a three-week use of live L. rhamnosus GG prevents the presence of 
human rhino- and enteroviruses in the nasopharynx or middle ear eff usion (I, II) or bacterial 
pathogens in the middle ear of young children (II).
3. Determine whether live or inactivated L. rhamnosus GG have diff erent eff ects on 
nasopharyngeal human rhinovirus load in experimental human rhinovirus infection and 
the correlation of the viral load to total clinical symptom score in adults (III).
4. Analyze the adverse events of L. rhamnosus GG alone and in specifi c combinations (with 
BB12, or PJS, Lc705, and/or BB99) in 1,909 children, young adults, and elderly in six 
randomized placebo-controlled studies (IV)
Aims of the Study
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4 MATERIALS AND METHODS
4.1 Subjects, study designs and data collec  on (I-IV)
4.1.1 Lactobacillus rhamnosus GG in the middle ear e  usion and 
adenoid  ssue (I, II)
Studies I and II were randomized, double-blind, placebo-controlled clinical intervention studies 
that used a two parallel-groups design (L. GG and placebo). Th e two studies were conducted in 
the same study setting and with the same study population in Helsinki, Finland from January 
to June 2011. Subjects aged 1 to 5 who were referred for adenotomy and tympanostomy for 
recurrent otitis media, secretory otitis media, chronic rhinitis and/or recurrent sinusitis were 
enrolled. Children with snoring as the principal diagnosis, chronic sinusitis, symptomatic 
allergy, chronic GI diseases, other chronic diseases, continuous use of inhaled asthma 
medication, immunosuppression, continuous antibiotic prophylaxis, or a course of antibiotics 
within four weeks prior to the study, milk allergy, lactose intolerance, participation in another 
study concurrently, and unwillingness to follow the study protocol, were excluded. A computer-
generated randomization list was used, and it remained concealed aft er all data were analyzed.
Th e study was conducted over a period of nine weeks. Th e fi rst four weeks were a wash-
out period, and any use of probiotic products was prohibited. Th e following three weeks were 
the intervention period when the children consumed either capsules containing L. GG (8-9 x 
109 cfu), or a placebo (crystalline cellulose) twice a day. During the intervention period, parents 
fi lled in a daily diary recording signs of respiratory infection (fever, rhinitis, sore throat, and 
cough), GI symptoms (diarrhea, vomiting, and abdominal pain), other possible symptoms, the 
use of any medication, and seeking medical care. At the end of the third week, the adenoid was 
removed, and if there was eff usion in the middle ear, the fl uid was collected via paracentesis and 
a tympanostomy tube was inserted. Th e adenoid tissue and MEE fl uid were frozen at -70 °C 
until the analysis. Th e fi nal two weeks of the study were a follow-up period. A daily diary was 
used to record information about respiratory and GI symptoms, postoperative pain or bleeding, 
medication, and seeking medical care. Th e follow-up period had no dietary restrictions. Th e 
study protocol is presented in Figure 2.














Figure 2. Th e study design in studies I and II. w = weeks
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4.1.2 Lactobacillus rhamnosus GG in experimental rhinovirus infec  on 
(III)
Study III was a randomized, placebo-controlled, double-blinded experimental study with a three 
parallel-group design (live, inactivated L. GG, and placebo). Th e study extended the analysis 
performed in a previous study (Kumpu et al. 2015). Th e study was conducted in Charlottesville, 
Virginia, USA, from August to November 2010. Healthy volunteers between 18 and 65 years were 
recruited. Th e exclusion criteria for the recruitment were as follows: signifi cant allergic rhinitis, 
lower respiratory tract diseases, nasal abnormalities, pregnancy, lactation, history of alcohol 
abuse, drug abuse during the past year, daily smoking within the past two years, participation 
in a clinical trial during the past month, previous participation in an experimental study with 
HRV A39, any surgical or medical condition, or use of any medication or dietary supplement 
that could disturb the results. A total of 198 volunteers were screened for serum-neutralizing 
antibody titers of 1:4 or less for the challenge virus, resulting in the selection of 84 subjects. Aft er 
24 subjects were excluded, 60 subjects were enrolled and advised not to consume any probiotic 
products for the three weeks preceding the intervention. Th ey were assigned a study number 
according to a random code that was generated by a statistician. 
Th e placebo and carrier product for the probiotics was commercially available fruit juice, 
100 ml of which was consumed daily for six weeks. Twenty subjects were randomized to receive 
juice enriched with live L. GG (109 cfu), 20 subjects to receive heat-inactivated L. GG (109 cfu), 
and 20 subjects to receive juice with no additives. Aft er consuming the study products for 
three weeks, every subject received inoculations with a 100–300 tissue culture infectious dose 
(TCID50) of HRV (immunotype 39) in the nasal cavity. Aft er inoculation, the subjects continued 
using the intervention products for another three weeks. Nasopharyngeal lavage specimens were 
collected before the inoculation and on days 1 to 5 aft er the inoculation for quantitative HRV 
analysis. Specimens were collected by dropping 5 ml of sterile 0.9% saline into each nostril when 
the subject’s head was tilted back. When the subject felt saline running in the naso-oropharynx, 
the head was bent forward and the fl uid was collected in a cup. During the six-week intervention 
period, the subjects used a daily diary to record URI symptoms (sneezing, runny nose, stopped 
up nose, sore throat, cough, headache, malaise, and chilliness). Additionally, the severity of the 
symptoms was recorded on the day of the inoculation and ive days aft er the inoculation by using 
a severity score from 0 (none) to 4 (very severe).
4.1.3 Adverse events of probio  cs (IV)
In study IV, we included six (Hatakka et al. 2001, Hatakka et al. 2007a, Hatakka 2007b, 
Hatakka et al. 2007c, Kumpu et al. 2012, Lehtoranta et al. 2014) of our study groups’ previous 
randomized, double-blinded, placebo-controlled studies to investigate the AEs of L. GG alone 




Table 3. Characteristics of the studies included in study IV
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5 and 3
Total no of subjects (probiotic/placebo) in analysis ²Mean (range), years ³Months PROM = patient 
reported outcome measure
Th ese studies were selected because they used a parallel group design and provided individual 
follow-up data on primary and secondary variables and possible AEs. Th e six studies also included 
a vast cohort of ages (toddlers, daycare children, conscripts, independent and institutionalized 
elderly), prolonged intervention periods (3–7 months), and no surgical intervention. Th e 
child population was healthy because one of the exclusion criteria was suff ering from any 
chronic disease (Hatakka et al. 2001, Hatakka et al. 2007a, Kumpu et al. 2012). In the conscript 
population, only continuous per oral corticosteroid use or probiotic consumption were exclusion 
criteria (Lehtoranta et al. 2014). Th e exclusion criteria in the elderly population were moderate 
to severe dementia, chronic GI diseases (Hatakka 2007b), or the use of oral yeast medication 
(Hatakka et al. 2007c).
In this study, we used the study populations included in the primary analyzes in the 
individual studies, which yielded 1,909 subjects. Th e intention-to-treat population (a total 
of 2,949 subjects) was also analyzed to compare and confi rm the results. Th e individual data 
on possible AEs were collected from daily diaries, clinical examinations, assigned diagnoses 
and medications, the AE form, and/or bacterial samples. All these data were assessed, and 
then all possible AEs were distributed into System Organ Classes I-XXVI, using the Common 
Terminology Criteria for Clinical Adverse Events 4.0 (CTCAE). AEs in diff erent System Organ 
Classes were recorded. Th ey then were compared in the probiotic groups and the placebo groups. 
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Th ree categories (Gastrointestinal [VII] and Respiratory, thoracic and mediastinal disorders 
[XXII] and Infections and infestations [XI]) were selected for the detailed analysis of AEs and for 
comparison between the diff erent probiotic combinations and placebos in the individual studies.
4.2 Bacteriological and virological methods
4.2.1 Lactobacillus rhamnosus GG extrac  on (I, II)
L. GG was investigated in the middle ear eff usion (I) and the adenoid tissue (II) samples. Bacterial 
DNA was extracted from the samples as described by Rinttilä et al. (2004). Th is extraction 
technique provides a quantitative lysis of all relevant microbial groups, thus ensuring non-biased 
measurements of microbial profi les. Th e total bacterial levels were quantifi ed with broad-range 
primers in Nadkarni et al. (2002) and levels of L. GG by primers in Ahlroos and Tynkkynen 
(2009). Th e melting curves in the PCR analysis were confi rmed to establish qPCR validity.
 
4.2.2  Bacterial microarray (I)
Bacterial microarray testing was performed using the collected MEE samples (I). DNA was 
extracted using EasyMAG (EasyMAG bioMérieux) with the Generic 2.0.1 program: 500 μl was 
added to the lysis of extraction device, and DNA was eluted to the 50 μl elution buff er. Th e PCR 
reactions in the extracted DNA were conducted by the Prove-it™ Bone and Joint StripArray 
assay (Mobidiag, Finland) according to the manufacturers´ instructions. Th e PCR protocol was 
carried out using Mastercycler® ep gradient S (Eppendorf, Germany). Aft er the PCR reactions, 
the amplicons were subjected to hybridization onto StripArray using the Prove-it™ protocol. Th e 
detection and analysis of bacteria were conducted with the StripArray Reader and Prove-it™ 
Advisor soft ware.
4.2.3 Picornavirus PCR (I, II)
Picornaviruses (HRV and EV) were analyzed in MEE (I) and adenoids (II). Buff er RLT (Qiagen, 
Hilden City, Germany) with Carrier RNA (Qiagen) was added to homogenize the samples. For 
the lysis, the samples were disrupted by pipetting and vortexing before they were incubated. A 
tissue lysate was added to a QIAshredder homogenizer (Qiagen) and then centrifuged. Aft er 
homogenization, the lysate was used for the viral nucleic acid extraction. Viral nucleic acids 
were purifi ed as described by Kumpu et al. (2013b) for HRV and EV PCR assays. Validated 
real-time RT-PCR methods were used to detect HRV and EV. Amplifi cation curves rising above 
the threshold were interpreted positively. Th e assays were run by using the Mx3005P analyzer 
(Stratagene, La Jolla, CA).
4.2.4 Quan  ta  ve human rhinovirus PCR (III)
HRV load was analyzed in the nasopharyngeal lavage samples (III). Th e quantitative amount 
of HRV was detected by a real-time PCR, where short double-dye probes with locked nucleic 
acid analogs were used as described by Österback et al. (Österback et al. 2013). Wild-type HRV 
infections were diff erentiated from the experimental HRV A39 infection by using additional 
melting curve dsDNA dye BOXTO analysis (Peltola et al. 2013, Österback et al. 2013). In selected 
cases, a sequence analysis was performed to confi rm the results.
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4.3 Sta  s  cal methods
Categorical variables were analyzed with Fisher’s exact test (I). Comparisons between the 
intervention groups were made using Levene’s test for equality of variances or the Mann–
Whitney U-test (I, II). In study III, the three intervention groups were compared by using an 
analysis of variance or the Kruskal–Wallis non-parametric test. Th e correlation between the 
HRV load and the total symptom score was calculated using Spearman’s correlation test. In 
study IV, the individual participant data were analyzed independently in each study by using 
risk ratios (RRs). A meta-analysis then was conducted using random eff ect models to estimate 
the overall RRs. Th ese models incorporated variations both within and between the studies. All 
RRs presented with 95% confi dence intervals. Th e statistical heterogeneity among the studies 
was assessed using Cochrane’s Q statistic, inconsistency was quantifi ed with the I2 statistic, and 
the guidelines were used for low, moderate, and high heterogeneity. 
A two-tailed P-value less than 0.05 was considered statistically signifi cant. Th e data were 
analyzed using IBM SPSS version 22 soft ware (IBM Corp., Armonk, NY, USA) and NCSS 8 
(NCSS LLC, Kaysville, Utah, USA).
4.4 Ethics
Th ese studies followed the guidelines of the Declaration of Helsinki and were accepted by 
the Ethics Committee of Helsinki University Hospital (I, II, IV) or the Human Investigation 
Committee of the University of Virginia (III). A personal data register was reported to the 
Finnish confi dentiality representative (IV). All subjects participated voluntarily, and a written 
informed consent was obtained from the study subjects or their legal guardians. Th e studies were 




5.1 Baseline characteris  cs (I, II)
Th e baseline characteristics of the children in studies I and II are presented in Table 4. Th ere were 
13 children in study I and 40 children in study II. Th e groups were statistically similar in their 
baseline information, with the exception of OME prevalence in study II (L. GG vs. placebo group 
P = 0.02).
Table 4. Baseline characteristics of the study children
Characteristics Study I
L. GG (n = 10) placebo (n = 3)
Age (median, months) 35.0 27.0
Male gender 8 3
MEE samples 19 6











Prior use of L. GG 8 2
Mother´s gestational use of probiotics 4 1
Numbers represent the number of children unless otherwise stated.
                                 
Characteristics Study II
L. GG (n=20) placebo (n=20)
Age (median, months) 40.5 35.0
Male gender 12 11
Adenoid samples 14 17
Capsules consumed (mean) 30.5 27.7










Prior use of L. GG 14 14
Mother´s gestational use of probiotics 5 7
*p = 0.02. Numbers represent the number of children unless otherwise stated.
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5.2 Lactobacillus rhamnosus GG in the middle ear e  usion 
and adenoid (I, II)
Twenty-fi ve MEE samples were available for the L. GG analysis. Among these, four of 19 (21%) 
in the L. GG group presented with L. GG; one of 6 (17%) in the placebo group presented with L. 
GG (fi ndings in L. GG vs. placebo group, P = 1.0). Traces of total bacterial DNA were detected in 
all 25 MEE samples. When the detection limit for total bacteria was set at > 3x106 16S copies/g, 
the percentages of total bacteria were 37% and 50% in the L. GG group and the placebo group, 
respectively (P = 0.65). 
Th irty-one adenoid samples were available for the L. GG analysis. Among these, all 14 
(100%) in the L. GG group presented with L. GG; 13 of 17 (76%) presented with L. GG in the 
placebo group (L. GG vs. placebo group P = 0.07). Only four samples (24%) were negative for L. 
GG, all of which were in the placebo group.
5.3 The e  ect of Lactobacillus rhamnosus GG on 
picornaviruses and bacterial pathogens, and symptoms in 
study diaries (I, II)
HRV and EV prevalence was studied in both MEE and adenoid tissue; 25 MEE samples and 30 
adenoids were available for analysis. HRV was present in 12 (48%) of the MEE samples and 7 
(23%) of the adenoid samples. Of the positive HRV fi ndings, 10 (83%) samples in the MEE and 4 
(57%) samples in the adenoid were in the L. GG group (L. GG vs. placebo P = 0.6 in MEE and P 
= 0.7 in adenoid). EV was present in 1 (4%) of 25 MEE samples (in the L. GG group, P = 0.8) and 
in 7 (23%) of 30 adenoid samples (4 in the L. GG group, P = 0.7) (see Table 5).
Table 5. Human rhinovirus and enterovirus -fi ndings in the middle ear eff usion and adenoid tissue, 
in the L. GG and placebo groups
HRV (%) EV (%)
MEE (n=25) 12 (48) 1 (4)
     L. GG (n=19) 10 (83) 1 (100)
     Placebo (n=6) 2 (17) 0
     P-value 0.6 0.7
Adenoid (n=30) 7 (23) 7 (23)
     L. GG (n=14) 4 (57) 4 (57)
     Placebo (n=16) 3 (43) 3 (43)
     P-value 0.8 0.7
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Pathogenic bacteria were analyzed in all 25 MEE samples; 15 (60%) of the samples presented with 
at least one bacteria species. Th e fi ndings between the groups did not diff er (12 in L. GG vs. 3 in 
the placebo group, P = 0.65). H. infl uenzae was the most prominent pathogen and was recovered 
from 12 (80%) samples (10 in the L. GG group, 2 in the placebo group, P = 0.6). Multiple bacteria 
were detected in four samples. Th e viral and bacterial fi ndings from the MEE samples in both 
groups are presented in Figure 3.
Figure 3. Th e bacteriological and virological fi ndings from 25 MEE samples in the L. GG and placebo 
groups Th e diff erences between the groups were not statistically signifi cant.
Th e daily diaries kept in the three-week intervention period and the two-week postoperative 
period were collected. Data on the symptoms are presented in Table 6. No statistically signifi cant 
diff erences were found between the intervention groups. Children with MEE tended to 
experience respiratory symptoms more frequently compared to those with dry ears but not 
signifi cantly (median 5.5 vs 0.5 days respectively, P = 0.16).
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Table 6. Information from the daily diaries in the intervention and postoperative periods. Numbers 
represent the mean number of symptom days within the observation period. No diff erences between 
the L. GG and the placebo group were statistically signifi cant.
INTERVENTION PERIOD L. GG (n = 17) PLACEBO (n = 15)
Respiratory symptoms 5.8 4.2
GI symptoms 0.7 1.5
Other symptoms 1.1 0.5
Use of medication 2.8 3.8
Need for medical care 0.6 1.3
POSTOPERATIVE PERIOD (n=13) (n=6)
Respiratory symptoms 3.6 2.5
GI symptoms 1.6 0.2
Bleeding 0.1 0.2
Pain 2.2 0.8
Other symptoms 1.0 1.2
Need for medical care 0.2 0.0
5.4 E  ect of Lactobacillus rhamnosus GG on experimental 
rhinovirus infec  on (III)
Data on 59 subjects (live L. GG n = 19, inactivated L. GG n = 20, placebo n=20) were available 
for analysis. Nasopharyngeal lavage samples on day 0 before inoculation, day 2, and day 5 were 
analyzed in the three intervention groups, resulting in a total of 177 analyzed samples. In nine 
(15%) subjects, the melting curve analysis and gene sequencing revealed a wild-type infection 
and thus a diff erent immunotype than the A39 that was used. Aft er excluding the wild-type 
infections, the analyzed samples were n = 18 in live L. GG, n = 16 in inactivated L. GG, and n 
= 16 in the placebo group. Th e results of the HRV load in nasopharyngeal lavage samples in the 
intervention groups are presented in Figure 4.
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Figure 4. Th e mean, 95% CI, and range on nasopharyngeal HRV load (log10) in days 2 and 5 in 
experimental HRV challenge in the three intervention groups. Grey = upper CI, orange = lower CI.
Th ere was a tendency to lower loads in the two L. GG groups (log10 copies/ml [95% CI]: 6.20 
[5.18-7.40] in live L. GG group, 6.30 [4.91-7.08] in inactivated L. GG group, and 7.25 [5.81-
7.52] in the placebo group). However, the diff erence between the groups was not statistically 
signifi cant (P = 0.57 on day 2 and P = 0.76 on day 5 in the excluded wild-type population). In the 
whole study population, mean (SD) HRV load (log10 copies/ml) was 3.31 (3.58) on day 2, and 
3.98 (2.66) on day 5. 
Th e mean (range) total symptom scores were 3.31 (14) and 3.39 (17) on days 2 and 5, 
respectively. A signifi cant positive correlation between HRV load and total symptom score on 
days 2 and 5 existed (correlation coeffi  cient 0.61, P <0.001 and correlation coeffi  cient 0.28, P = 












































Figure 5. Correlations between human rhinovirus load in nasopharyngeal lavage samples and total 
symptom scores on day 2 aft er inoculation in the three intervention groups
Figure 6. Correlations between human rhinovirus load in nasopharyngeal lavage samples and total 
symptom scores on day 5 aft er inoculation in the three intervention groups.
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5.5 Adverse events of speci  c probio  c species (IV)
Th e individual data on 1,909 study subjects revealed AEs in 20 of the 26 CTCAE groups. Th e 
highest incidence (79.2%) was found in the System Organ Class (SOC) of Respiratory, thoracic 
and mediastinal disorders (XXII). Considerable incidence also occurred in gastrointestinal 
disorders (VII, 73%), general disorders and administration site conditions (VIII, 62.6%) and 
infections and infestations (XI, 48.2%). Th e CTCAE groups and the AE incidences are presented 
in Table 7.
























I Blood and lymphatic 
system disorders
0.0 0.0 0.0 0.0 0.0
II Cardiac disorders 0.0 0.2 0.0 8.9 0.9
III Congenital, familial 
and genetic disorders
0.0 0.0 0.0 0.0 0.0
IV Ear and labyrinth 
disorders
13.0 33.9 40.9 80.7 1.6 32.8
V Endocrine disorders 0.0 0.2 0.0 2.6 0.3
VI Eye disorders 13.0 84.4 18.1 11.9 3.1 30.4
VII Gastrointestinal 
disorders
29.8 84.4 75.2 93.7 47.8 84.4 73.0
VIII General disorders 
and adm. site cond.
51.4 83.0 71.0 96.3 16.8 5.7 62.6
IX Hepatobiliary 
disorders
0.0 0.0 0.0 0.0 0.0
X Immune system 
disorders
0.0 4.2 1.1 1.0 1.4
XI Infections and 
infestations
85.1 59.7 23.6 85.5 33.6 9.4 48.2
XII Injury, poisoning 
and procedural 
complications
0.0 11.4 0.2 1.9 4.7 3.8
XIII Investigations 0.0 0.0 0.0 38.0 3.8
XIV Metabolism and 
nutrition disorders
0.0 0.2 0.4 5.2 0.6
XV Musculoskeletal 
and connective tissue 
disorders
30.8 9.4 1.5 21.9 8.2
XVI Neoplasm 
benign, malignant and 
unspecifi ed


























XVII Nervous system 
disorders




0.0 0.0 0.0 0.0 0.0
XIX Psychiatric 
disorders
0.0 0.0 1.9 1.0 0.4
XX Renal and urinary 
disorders
0.0 2.8 2.2 2.6 1.3
XXI Reproductive 
system and breast 
disorders




98.1 95.6 91.0 99.6 39.4 2.6 79.2
XXIII Skin and 
subcutaneous tissue 
disorders
7.2 15.4 12.3 0.0 6.5
XXIV Social 
circumstances
0.0 0.0 0.0 0.0 0.0
XXV Surgical and 
medical procedures
0.0 79.8 0.4 76.6 28.7
XXVI Vascular 
disorders
0.0 0.0 0.0 6.8 0.7
Th e AEs reported in the specifi c System Organ Classes in the comparison between the probiotic 
and placebo groups are presented in Figure 7. Risk ratio over one, which favors the placebo, 
was found in fi ve System Organ Classes: cardiac disorders (II), injury, poisoning and procedural 
complications (XII), metabolism and nutrition disorders (XIV), nervous system disorders 





Figure 7. Risk ratios and 95% confi dence intervals of AEs in specifi c CTCAE categories between the 
probiotic and placebo groups.
Th e detailed analysis of gastrointestinal disorders (CTCAE category VII), yielded the overall RR 
of AEs in the probiotic group vs. the placebo group of 0.97 (95% CI 0.93–1.02, P = 0.30). Th e 
results appeared to favor probiotics in specifi c studies (RR 0.73-1.08) and in diff erent probiotic 
combinations (RR 0.99-1.00). Th e dispersion of respiratory, mediastinal and thoracic disorders 
(XXII) was greater in diff erent studies, but the corrected weight of the overall RR of AEs in 
the probiotic group vs. the placebo group was 0.99 (95% CI 0.97–1.01, P=0.35). In the class of 
infections and infestations (XI), dispersion occurred between the studies, and the overall RR of 




Th e studies conducted in this thesis investigated probiotic Lactobacillus rhamnosus GG in 
the upper respiratory tract and the safety of specifi c probiotic species. Th e objectives were to 
determine whether L. GG colonized the upper respiratory epithelium, whether potential 
colonization had an eff ect on subjects’ microbiota, whether L. GG aff ected the nasopharyngeal 
rhinovirus load, and whether the use of specifi c probiotics, specifi cally L. GG, resulted in adverse 
events.
6.1 Coloniza  on of the upper respiratory tract by 
Lactobacillus rhamnosus GG
Th e two prospective, randomized, double-blinded, placebo-controlled studies (I, II) indicated 
that L. GG is able to colonize upper respiratory tract mucosa aft er per oral administration in 
the following locations: the eff usion in middle ear cavity and adenoid tonsil. Previously, L. GG 
(Kumpu et al. 2013a) and Lactobacillus plantarum DSM9843 (Stjernquist-Desatnik et al. 2000) 
were recovered from tonsillar tissue, and Streptococcus sanguinis K12 (Power et al. 2008) and 
Streptococcus salivarius 24SMBc (Santagati et al. 2015) were recovered from the nasopharynx. 
Th e fact that L. GG also was recovered in a portion of the samples in the placebo group may 
indicate a longer persistence or the accidental consumption of products containing L. GG. In 
addition, maternal transmission during delivery or breastfeeding is possible.
Th e mechanism by which L. GG is able to colonize upper respiratory epithelium is unknown. 
Th e mechanism of adhesion to gut epithelium is hypothesized to occur partly in the pilus-like 
structures that coat L. GG bacteria (Kankainen et al. 2009). Pili and the surface of L. GG contain 
mucus-binding proteins, which presumably play a role in epithelial adhesion (von Ossowski et 
al. 2010, von Ossowski et al. 2011, Tripathi et al. 2013, Nishiyama et al. 2015). Interestingly, 
pili are also implicated in L. GG adhesion to macrophages (Vargas Garcia et al. 2015). Pili also 
seem to have immunomodulatory interactions with the host (Zakaria Gomaa 2013). We can 
only hypothesize that the adherence of L. GG to the adenoid epithelium occurs in the same 
mechanism as it does in the gut epithelium. Colonization of the MEE could be explained by 
the migration of L. GG from the nasopharynx to the middle ear via the eustachion tube, which 
is thought to be the route for otitis media (OM) pathogens (Sadé 1994, Coticchia et al. 2013). 
In addition, diff erent applications and dosages should be studied because probiotic nasal spray 
therapy results in the colonization of the nasopharynx (Santagati et al. 2015), and diff erent 
applications and dosages may induce diff ering eff ects.
Th e nasopharyngeal and adenoid microbiota is a complex interactive system, and the 
consequences of changing the proportions, such as by probiotic colonization, remain unknown. 
Th e nasopharynx harbors a wide variety of bacteria and viruses, both commensal and pathogenic 
(Chi et al. 2003, Skevaki et al. in press). Th e bacterial composition of nasopharyngeal microbiota 
diff ers from other body parts, which was surveyed in healthy Chinese young adults (Ling et 
al. 2013). Th e nasopharyngeal microbiota presented with potentially invasive bacteria, such as 
Streptococcus pneumoniae, H. infuenzae, Staphylococcus aureus, M. catarrhalis, and Neisseria 
meningitidis in an overall healthy population (Bogaert et al. 2011, Hendley et al. 2005). In 
children, the nasopharyngeal microbiota was noted to change according to the season (Bogaert et 
al. 2011). Furthermore, certain commensal taxa were found to be negatively associated with AOM 
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pathogens, and the proportions of taxa changed depending on the use of antibiotics (Pettigrew 
et al. 2012). Respiratory viruses have been shown to accomplish changes in bacterial adhesion 
(Avadhanula et al. 2006), colonization (Tong et al. 2001) and immunological mechanisms 
(Colamussi et al. 1999) in the nasopharynx. Eventually, complex interactions between viruses 
and bacteria in the nasopharyngeal epithelium can evoke bacterial superinfections (Bakaletz 
1995).
Th e MEE has been extensively studied, but not with regard to the presence of probiotics. 
Th e introduction of PCR revealed a larger proportion of pathogens in MEE than previously 
was thought (Ueyama et al. 1995, Hotomi et al. 1993). Furthermore, the same pathogens were 
recognized in childhood OME and rAOM (Stol et al. 2013). Th e sensitivity of PCR also revealed 
the polymicrobial nature of otitis media (Pettigrew et al. 2011, Nokso-Koivisto et al. 2004, 
Holder et al. 2012, Marom et al. 2012, Nokso-Koivisto et al. 2015). Th e role of nasopharyngeal 
microbiota in the development of AOM or OME is strongly suggested (Tomonaga et al. 1989, 
Saylam et al. 2010, Liu et al. 2011, Ruohola et al. 2013). 
Th e importance of bacterial biofi lms in the middle ear has emerged during the last decade 
(Post et al. 2004, Fergie et al. 2004, Post et al. 2007). Biofi lms are organized heterogeneous 
bacterial communities that attach to surfaces and produce their own matrix; they have a higher 
antibiotic resistance than their planktonic (free-fl oating) counterparts (Macassey, Dawes 2008). 
One of the fi rst studies to indicate a viable structure in culture-negative OME found that the 
bacterial messenger RNA in MEE established metabolically active, intact organisms (Rayner et al. 
1998). It was shown that the naturally existing probiotics Lactobacilli and Bifi dobacteria are able 
to form biofi lm in the gut (Macfarlane et al. 2011). Furthermore, in vitro experiments indicate 
that L. GG has the capacity to form biofi lm, in contrast to other strains of the Lactobacillus casei 
group (Lebeer et al. 2007). Our results did not confi rm the possibility of determining whether L. 
GG presented in the MEE and adenoid samples as a biofi lm or a planktonic. 
Nevertheless, the ability of probiotics to interfere with biofi lm formation in vivo has been 
partly studied (Vuotto et al. 2014). Interestingly, Lactobacillus reuteri biofi lms are capable of 
modulating the host’s immune responses and producing antimicrobial agents (Jones, Versalovic 
2009). Furthermore, the biosurfactants produced by Lactobacilli species showed multiple anti-
adhesive and antimicrobial activities against several pathogens (Zakaria Gomaa 2013). Probably 
the best initial evidence of probiotics in biofi lm-associated infections is found in dental practice 
against caries and plaque (Laleman, Teughels 2015, Gungor et al. 2015). However, the results are 
contradictory, and no conclusion on probiotic actions in biofi lms can be drawn yet (Ahmed et al. 
2014, Schwendicke et al. 2014).
It has been suggested that nasopharyngeal microbiota could aff ect subjects’ vulnerability 
to respiratory infections. In an experimental HRV challenge trial, signifi cant diff erences in 
two nasopharyngeal genera (Neisseria and Propionibacterium) were identifi ed between HRV-
infected and non-infected subjects (Allen et al. 2014). Furthermore, a previous study showed 
that young children presented with a small number of bacterial taxa in high total numbers in 
their nasopharynx, contrary to their parents who presented with much more diverse taxa 
with lower bacterial carriage (Stearns et al. 2015). Th is fi nding suggests that a greater variety 
of nasopharyngeal microbiota could protect the subject against URI. It is possible that the 
maturation of the host-associated microbial community happens similarly in the nasopharyngeal 
area and in the gut (Adlerberth et al. 2009). Interestingly, the development of nasopharyngeal 
microbiota was studied in 60 healthy infants, and certain microbiota patterns were found to 
be associated with decreases in URI episodes reported by the parents (Biesbroek et al. 2014). 
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Furthermore, nasopharyngeal microbiota, especially Streptococcus, has been implicated to 
children’s risk of developing asthma (Teo et al. 2015). Th ese aspects of microbial diversity in the 
nasopharynx are also considered when breastfeeding is recommended (Biesbroek et al. 2014, 
Berrington et al. 2014).
Microbes can adhere directly to each other, but eff ects can also occur through adhesion 
on  the host’s mucosal surfaces. Highly evolved relationships between the upper respiratory 
microbiota exist, and it is important to understand those interactions, especially when the 
microbiota is manipulated. In probiotic settings, knowledge of the colonization of the respiratory 
epithelium is valuable for further research to investigate the eff ects of probiotics on the natural 
microbiota.
6.2 E   cacy of Lactobacillus rhamnosus GG to speci  c upper 
respiratory infec  on pathogens
We studied the prevalence of HRV and EV in adenoid and MEE (I, II), and HRV load in 
nasopharyngeal lavage samples (III) aft er the oral consumption of L. GG. Interestingly, the 
percentages of the HRV- and EV- positive samples were higher in the L. GG group compared 
to the placebo, but the diff erence was not statistically signifi cant. In contrast, there was a slight 
tendency to lower HRV loads in the nasopharyngeal lavage samples in the live and inactivated 
L. GG populations compared to the placebo. However, these studies are not comparable because 
their settings and objectives are diff erent.
Th e results of the fi rst study showed a similar prevalence of respiratory symptoms in the 
L. GG and placebo groups. In previous studies, L. GG alone or in combination reduced the risk 
of upper respiratory infections in children (Kukkonen et al. 2008, Rautava et al. 2008, Hojsak 
et al. 2010b, Hojsak et al. 2010a, Kumpu et al. 2012). Moreover, the risk of HRV infections was 
signifi cantly lower in preterm infants using L. GG supplementation compared to the placebo 
(Luoto et al. 2013). However, in that study no signifi cant diff erences were observed between the 
groups in the clinical symptoms of HRV infection, HRV load, or duration of HRV infection. 
However, studies have found confl icting results regarding the  eff ects of L. GG on URI in adult 
subjects. In training marathon runners, L. GG did not have an eff ect on respiratory infections 
(Kekkonen et al. 2007). In contrast, in college students, the consumption of L. GG and BB12 
combined resulted in signifi cantly shorter and less severe URI symptoms compared to the 
placebo. In addition, the number of absences from school was signifi cantly fewer in the probiotic 
group (Smith et al. 2013). 
Many effi  cacy studies lack information about viral etiology. Virological fi ndings in 
symptomatic URI patients using L. GG and BB12 combined were studied in military conscripts 
(Lehtoranta et al. 2014). In that trial, a reduction in the total number of HRV- and EV-positive 
samples was noted aft er three months of using the probiotic mixture. Th e knowledge of L. GG’s 
eff ects on picornavirus (HRV and EV) infections is still insuffi  cient, so further effi  cacy trials are 
recommended to investigate the origin of the virus.
No signifi cant diff erences were found in the presence of pathogenic bacteria in MEE 
between the L. GG and placebo groups. Our result aligns with a previous study, in which a 
probiotic mixture with L. GG did not reduce the occurrence or recurrence of AOM in otitis-
prone children, and it did not have an eff ect on the nasopharyngeal carriage of S. pneumoniae or 
H. infl uenzae (Hatakka et al. 2007a). In addition, in another study with children at high-risk for 
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AOM, a probiotic and prebiotic combination did not reduce the incidence of AOM or antibiotic 
prescriptions; however, the combination did not contain L. GG (Cohen et al. 2013). However, 
there might be a diff erence in the effi  cacy of L. GG preventing AOM between otitis-prone and 
healthy children. Th e children in our studies (I, II) are the former. 
In a meta-analysis, L. GG was associated with lower risk of otitis media and antibiotic 
prescriptions in children (Liu et al. 2013). Infants fed with L. GG and BB12 enriched formula had 
a signifi cantly lower risk for AOM and antibiotic prescriptions during the fi rst seven months of 
life compared to the placebo group (Rautava et al. 2008). Moreover, in that study, the probiotic-
fed infants showed a tendency to the reduced need for tympanostomy. It is possible that effi  cacy 
is also dependent on the application form (capsule, powder, dairy product, or nasal spray) and 
manufacturing process (Grzeskowiak et al. 2011).
Th e mechanism by which L. GG might modulate the risk of AOM has received little attention. 
Alterations in the nasal or nasopharyngeal microbiota may infl uence the risk of AOM. Indeed, 
the consumption of probiotic (L. GG, Streptococcus thermophilus, Lactobacillus acidophilus, and 
Bifi dobacterium sp.) yogurt resulted in a signifi cant reduction in potentially pathogenic bacteria 
(Staphylococcus aureus, S. pneumoniae, β-hemolytic streptococci, and H. infl uenzae) in the nasal 
cavity (Glück, Gebbers 2003). In vitro, L. GG was able to inhibit the invasion of macrolide-
resistant group A streptococci in human epithelial cells (Princivalli et al. 2009). L. GG has also 
been indicated to inhibit the adherence of S. pneumoniae to epithelial cells in vitro (Wong et al. 
2013). It is possible that the adhesion of probiotics to epithelium or to mucus forms a protective 
layer against pathogenic bacteria, and probiotics might compete with pathogenic bacteria for 
binding sites (Popova et al. 2012). Th e ability of probiotics to aggregate among themselves or 
with other bacteria in order to form an adequate mass is also needed to promote natural barrier 
action (Collado et al. 2007). In addition, L. GG is capable of immunomodulation through cell-
mediated and humoral immunity (Fang et al. 2000, Cross 2002, Pohjavuori et al. 2004, Viljanen 
et al. 2005, Kukkonen et al. 2006, Oksaharju et al. 2011, Miettinen et al. 2012).
Our results for bacterial DNA and microarray revealed the dominance of H. infl uenzae 
in MEE. H. infl uenzae was recognized as a major pathogen in OME (Leskinen et al. 2002, 
Pichichero et al. 2008, Holder et al. 2012, Stol et al. 2013). However, new insights were gained 
as confocal laser scanning microscopy revealed a wide variety of live bacteria in MEE, including 
biofi lm (Daniel et al. 2012). Surprisingly, none of our samples presented with S. pneumoniae. 
One explanation might be vaccination; the pneumococcal conjugate vaccine had been 
implemented in a national vaccination program the year prior to our study. Th e introduction of 
the pneumococcal conjugate vaccine has been shown to alter the microbiology of AOM (Block 
et al. 2004, Zhao et al. 2014). Similar results in OME have shown decreases in the prevalence of 
S. pneumoniae and increases in the prevalence of H. infl uenzae (Holder et al. 2015). Our fi ndings 
support these previous results. 
In the nasopharyngeal lavage sample, we found no signifi cant diff erences in HRV load 
between the intervention groups. Moreover, in this sample size, a real eff ect could not be estimated 
(III). Th e 15%-prevalence of wild-type infections was rather high, but the study was conducted 
during the peak months in the fall. Similar to our results, in a study with preterm infants, no 
signifi cant diff erences emerged in HRV load between L. GG and placebo groups (Luoto et 
al. 2013). Furthermore, in that study, the relative HRV copy numbers did not correlate to the 
severity of symptoms, but they did correlate positively with the duration of the infection. In viral 
mouse models, L. GG signifi cantly reduced infl uenza virus titers in the lungs of experimentally 
infected mice (Kawase et al. 2010), and heat-killed lactobacilli showed the same capacity (Maeda 
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et al. 2009, Kawase et al. 2012). Obviously, there is a need for further clinical trials to investigate 
the viral occurrence and load to confi rm or disregard the eff ects of probiotics.
In our study, there was a positive correlation between HRV load and total symptom scores 
on day 2 and day 5 aft er inoculation. Previously, an association was found between higher 
nasopharyngeal HRV loads and clinical symptoms in upper and lower respiratory infections 
(Gerna et al. 2009). In lung transplant patients, nasopharyngeal HRV load positively correlated 
with certain symptoms (a sore throat, fever, cough, and sputum production) (Ambrosioni et al. 
2015). Furthermore, in an experimental study on HRV infection, a correlation between lower 
respiratory symptoms and nasal viral load was noted in the asthmatic subjects but not in the 
control subjects (Message et al. 2008). Another experimental HRV trial with chronic obstructive 
pulmonary disease (COPD) patients revealed similar results. Th e sputum virus load correlated 
with infl ammatory markers in the COPD subjects but not in the control subjects (Mallia et 
al. 2011). On the contrary, in natural viral respiratory infections, a correlation between HRV 
load and lower respiratory symptoms was not found in the asthmatic or the control subjects 
(van Elden et al. 2008). However, in children aged over 11 months, a strong positive correlation 
between nasopharyngeal HRV load and disease severity was found but not in younger infants 
(Takeyama et al. 2012). Furthermore, children diagnosed with HRV did not show a correlation 
between nasopharyngeal viral load and the severity of the disease, but the subjects with HRV 
viremia had a signifi cantly higher viral load and a more severe disease (Esposito et al. 2014). 
Our results showed a stronger positive correlation 48 h aft er inoculation when the symptoms 
(Gwaltney Jr. et al. 2003) and virus titers (Hendley et al. 2004) were observed to peak.
Th e dose and duration of the probiotic seem to infl uence its effi  cacy. We used moderate 
dosages of L. GG in the studies: 8-9 x 109 in I and II and 1 x 109 in III. It was shown that in 
gnotobiotic pigs, the eff ects of L. GG in adjuvanticity and protection against rotavirus diarrhea 
depended on the dosage (Wen et al. 2015). Two Japanese studies that investigated Lactobacillus 
casei strain Shirota in URI found better outcomes with a daily dose of 1 x 1011 than with a daily 
dose of 4 x 1010 (Fujita et al. 2013, Shida et al. in press). Moreover, because diff erent strains have 
diff erent eff ects, they should be studied separately.
6.3 Safety of probio  cs
We utilized the individual participant data on 1,909 patients in prospective randomized placebo-
controlled double-blinded studies that were conducted by our study group. Th ese data off ered 
a novel perspective on the analysis of the possible AEs of probiotics. In a healthy population of 
children, young adults, and the elderly, the consumption of L. GG or L. GG in combination with 
BB12, or PJS, Lc705 and/or BB99 did not result in AEs that diff ered from those in the population 
that used a placebo. Th e detailed analysis of the categories of respiratory and gastrointestinal 
diseases and infections, including specifi c combinations of them, did not show any statistical 
diff erences in AEs. 
Because the consumption of probiotics is becoming increasingly widespread, clinicians 
should understand the risks and benefi ts regarding their use. Probiotics are considered dietary 
supplements, so they are not subject to the same regulation and safety assessment that drugs are 
(Boyle et al. 2006, Degnan 2008). Th e general consideration of commercially available probiotics 
is that they are safe (Ishibashi, Yamazaki 2001). However, although the use of probiotics has raised 
some concerns about their safety, the topic has not been suffi  ciently studies (Sanders et al. 2010). 
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Indeed, rare occasions of sepsis (Land et al. 2005), fatal infection in an immunocompromised 
patient (Kalima et al. 1996), and increased mortality in patients with severe pancreatitis 
(Besselink et al. 2008) have been implicated in the use of probiotics. However, the European 
Food Safety Authority (EFSA) has granted the qualifi ed presumption of safety (QPS) to many 
commercial probiotic strains, as well as to L. GG (EFSA 2013). Probiotic bacteria in food should 
fulfi ll the following criteria: they should be non-pathogenic; they should not pose a risk to the 
host; the absence of virulence genes should be proved; and the absence of antibiotic resistance 
should be proved (Wassenaar et al. 2008). Because diff erent genera and strains have diff erent 
clinical eff ects, AEs should be assessed in a strain-specifi c manner.
Several systematic reviews and meta-analyses of probiotic safety have been conducted 
(Didari et al. 2014, Whelan et al. 2010, Hempel et al. 2011). However, because the majority of 
these studies did not investigate the safety of probiotics, there is a major lack of assessment and 
systematic reporting of AEs. Furthermore, many of these studies have been inconsistent and 
incomplete in reporting possible AEs. Th us, the evidence that there is no increase in the risk 
of probiotic consumption must be viewed in a critical light. A Dutch-led study group used the 
CTCAE as a systematic evaluation tool in three meta-analyses of probiotic safety in diff erent 
populations: infants under two years of age (van den Nieuwboer et al. 2014); children under 
18 years of age (van den Nieuwboer et al. 2015b); and immunocompromised adults (van den 
Nieuwboer et al. 2015a). In every one of these meta-analyses, relatively more AEs occurred in 
the control group than in the probiotic group. However, the writers have emphasized limitations 
in the reporting and classifi cation of AEs, and they therefore caution against the generalization 
of their conclusions. Because of the precise reporting and classifi cation used in our study, our 
results contribute to the information about the safety of specifi c probiotics. 
6.4 Strengths and limita  ons
Th e strengths of this series of studies are the following. Th ey are prospective, randomized, 
double-blinded, placebo controlled, and well designed, including the six studies used in study IV. 
Th e limitations of the studies are the following. Th ere was a high number of drop-out subjects 
and a small sample size in studies I, II, and III. In addition, it is confusing that a high number of 
placebo samples was recovered with L. GG.
Th e results of study IV could be generalized. Th is study used a wide range of multiple 
subjects, and the results were confi rmed. We also demonstrated the ability of L. GG to colonize 
the nasopharynx and the middle ear in children but not in adults. Furthermore, the eff ects of L. 
GG on viral and bacterial pathogens could not be confi rmed in these studies.
6.5 Future research
Over the past decades, gut microbiota has been increasingly recognized as one of the main 
factors in the increasing prevalence of immunity-related disorders, such as infl ammation, atopy, 
asthma, musculoskeletal disorders, liver fi brosis, diabetes mellitus type 2, metabolic syndrome, 
cardiovascular diseases, neurodegenerative diseases, atherosclerosis, and cancer, which is also 
known as the hygiene hypothesis (Bubnov et al. 2015). Th e research on metagenomics has 
contributed information on how the microbiota interacts with the host’s physiology and has 
started to provide new therapeutical targets. Finally, by better understanding the role of gut 
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microbiota, the individual’s microbiota could be integrated into personalized healthcare, and 
the individual’s diseases could be targeted and treated more effi  ciently. However, the complete 
understanding of the disease process is required to determine whether targeting gut microbiota 
would be eff ective or not (Marchesi et al. in press).
We showed that, in addition to the gut and the beginning of the GI-tract (oral cavity and 
oropharynx), probiotics are able to colonize the respiratory tract. Because adenoids are part 
of the active lymphatic tissue of the Waldeyer’s ring, their colonization might have eff ects 
that are similar those in the gut epithelium. Commensal and probiotic organisms in the gut 
are able to trigger the production of host proinfl ammatory and antimicrobial proteins and 
peptides (Sassone-Corsi, Raff atellu 2015). Th ese are also implicated in the activation of innate 
immune responses and are able to promote adaptive immune responses. Th ey also involve the 
diff erentiation of T cells and the diff erentiation and activation of B cells.
Gut microbiota and probiotics have been widely studied and implicated in immunity-related 
diseases, such as cardiovascular disease (Ryan et al. 2015), rheumatoid arthritis (Sandhya et al. 
in press), metabolic diseases (Ojeda et al. in press, Le Barz et al. 2015), allergies (Vernocchi et 
al. 2015), gynecologic cancers (Chase et al. 2015), gestational diabetes (Isolauri et al. 2015), and 
perhaps the most surprisingly, the function of the brain (Liu et al. 2015). However, we do not 
know whether the eff ects of probiotics in URI are caused by altered gut microbiota or by the local 
respiratory epithelium. In the coming decades, the research on infl ammatory diseases will off er 




Based on the results presented in this thesis, the following conclusions are drawn regarding 
the colonization of Lactobacillus rhamnosus GG in the upper respiratory tract and its eff ects on 
pathogens in the upper respiratory tract, including adverse events of Lactobacillus rhamnosus 
GG and other probiotics:
1. L. rhamnosus GG was recovered from 100% of adenoid tonsil samples and 21% of 
middle ear eff usion samples aft er a three week per oral consumption of the probiotic 
in children admitted to adenotomy and possible tympanostomy. Because L. rhamnosus 
GG also was recovered in 76% of the adenoid tonsil samples and 17% of the middle ear 
eff usion samples of the placebo group, persistence longer than seven weeks, which was 
the length of the wash-out plus the intervention period, may occur.
2. Th e consumption of L. rhamnosus GG did not aff ect the number of human rhinovirus 
and enterovirus -positive samples of the adenoid or middle ear eff usion, or the bacterial 
presence in the middle ear eff usion in children with recurrent acute otitis, otitis media 
with eff usion, or chronic sinusitis. Based on the study diaries, it did not result in notable 
diff erences in clinical symptoms.
3. Live or inactivated L. rhamnosus GG did not signifi cantly aff ect the human rhinovirus 
load in the nasopharyngeal lavage samples compared to the placebo in an experimental 
human rhinovirus challenge in healthy adult volunteers. Th e human rhinovirus load 
was positively correlated with total clinical symptom scores on days 2 and 5 aft er 
inoculation with the experimental human rhinovirus.
4. Th e use of L. rhamnosus GG alone or in combination with BB12, or PJS, Lc705, and/
or BB99 did not result in adverse events in healthy child, young adult, or elderly 
populations according to the individual participant data on 1,909 subjects in six 
prospective randomized, placebo-controlled, double-blinded studies. No notable 
adverse events were observed to result from the consumption of these probiotics, 
which were distributed according an organized classifi cation scale, the Common 
Terminology Criteria for Adverse Events. A detailed analysis was conducted in three 
categories: respiratory, gastrointestinal disorders, and infections. Th e results showed 
similar adverse events between the probiotic compounds and placebos assigned in the 
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